JPMorgan raised the firm’s price target on Revolution Medicines (RVMD) to $71 from $70 and keeps an Overweight rating on the shares. The firm updated the company’s model, saying it has developed a “compelling set” of RASi inhibitors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- These 2 Stocks Could Be Prime Takeover Targets, According to Analysts
- Revolution Medicines resumed with a Strong Buy at Raymond James
- Revolution Medicines rises 14.2%
- Morning Movers: Kroger rises following second quarter results
- Revolution Medicines announces results from daraxonrasib Phase 1 trials